AtriCure projects 2026 adjusted EBITDA of $91M-$94M as it targets BoxX-NoAF enrollment completion by year-end

AtriCure Q3 2026 earnings: revenue rose 15%, EBITDA outlook increased, and BoxX-NoAF nears enrollment amid market headwinds.

CryptoAlerta — análise de criptomoedas e mercado em tempo real